Life Sciences Archives - Page 2 of 16 - EverGlade

Life Sciences

BARDA Signals Major NPIVS Contract For Pandemic Influenza Vaccines And Adjuvants

Leave a Comment / All Posts, BARDA, Industry News, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA) has quietly dropped a pre‑solicitation notice for a major, long‑term contract to sustain and expand the Vaccine Medical Countermeasures (MCMs) for Pandemic Influenza Preparedness and Response Program, including the U.S. National Pre‑pandemic Influenza Vaccine Stockpile (NPIVS). The notice, posted July 30, 2026 under solicitation number 75A50126R00001, is […]

BARDA Signals Major NPIVS Contract For Pandemic Influenza Vaccines And Adjuvants Read More »

Coming Soon From ARPA-H: FASTPASS For Rapid Screening of Medicines  

Leave a Comment / All Posts, ARPA-H, Industry, Life Sciences / By

The Advanced Research Projects Agency for Health (ARPA‑H) is launching the Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and Supplies (FASTPASS) program to tackle a critical, often invisible problem in the U.S. healthcare system: substandard and contaminated medicines slipping through the supply chain. Drug-related morbidity and mortality cost the system an estimated $528 billion per year and recalls affect the

Coming Soon From ARPA-H: FASTPASS For Rapid Screening of Medicines   Read More »

BARDA Seeks Advanced Dermal Regeneration Solutions for Severe Burns

Leave a Comment / All Posts, BARDA, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice titled “Advanced Dermal Regeneration Substitutes for Treatment of Severe Burns and Complex Traumatic Injuries” (BARDA-CBRN-07282026) to identify commercially available or near commercial technologies that address large-area skin loss from burns and traumatic injuries in a mass casualty setting. This notice is for

BARDA Seeks Advanced Dermal Regeneration Solutions for Severe Burns Read More »

NIH’s Unified Funding Strategy Signals a New Approach to Award Decisions

Leave a Comment / All Posts, Industry News, Life Sciences / By

The National Institutes of Health (NIH) is starting to roll out its new Unified Funding Strategy, originally announced in late 2025, to support more informed, transparent, and flexible funding decisions across its Institutes, Centers, and Offices. Peer review remains central to NIH’s process, but funding decisions will now draw on the full body of review

NIH’s Unified Funding Strategy Signals a New Approach to Award Decisions Read More »

ASPR’s New Five Year Plan: Reading the Fine Print on Medical Countermeasure Funding

Leave a Comment / All Posts, Industry News, Life Sciences / By

The Administration for Strategic Preparedness and Response (ASPR) has quietly dropped one of the most important funding documents of the year: the 2025–2029 Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Multiyear Budget (MYB). On paper, it is a five‑year budget plan across: The Administration for Strategic Preparedness and Response (ASPR) The Biomedical Advanced Research and

ASPR’s New Five Year Plan: Reading the Fine Print on Medical Countermeasure Funding Read More »

ARPA-H’s Special Notice Supports Executive Order on Serious Mental Illness and OUD

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

The Advanced Research Projects Agency for Health (ARPA‑H) has released Special Notice ARPA‑H‑SN‑26‑156 under its Proactive Health Office (PHO), focusing on early clinical development of ibogaine for opioid use disorder (OUD).  This Special Notice sits under ARPA‑H’s Proactive Health Office Innovative Solutions Opening (ISO PHO‑SOL‑24‑106), which is an open solicitation for “revolutionary solutions” that do not

ARPA-H’s Special Notice Supports Executive Order on Serious Mental Illness and OUD Read More »

HHS & VA’s MOU is Building the Data & Regulatory Backbone for Veterans’ Mental Health 

Leave a Comment / All Posts, Industry News, Life Sciences / By

The Departments of Health and Human Services (HHS) and Veterans Affairs (VA) have entered a five‑year Memorandum of Understanding (MOU) to coordinate on rapid‑acting treatments for substance use disorders and mental health conditions in veterans, including psychedelic drug products.  In parallel, the HHS/FDA and VA have signed MOU 225‑26‑007, which lays out how the agencies will collaborate and share information

HHS & VA’s MOU is Building the Data & Regulatory Backbone for Veterans’ Mental Health  Read More »

New DARPA RFI: Multiscale Reasoning Across Human Physiology

Leave a Comment / All Posts, DARPA, Life Sciences / By

The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), has released RFI DARPA‑SN‑26‑100 on “Multiscale Reasoning for Human Physiology.” The agency is seeking input from organizations that can connect human biology from molecules to clinical outcomes in support of military medicine. The focus is on prediction, diagnosis, intervention, and recovery in

New DARPA RFI: Multiscale Reasoning Across Human Physiology Read More »

BARDA RRPV RFI Seeks Partners for BSL4 Studies and Support Services 

Leave a Comment / All Posts, BARDA, Life Sciences / By

Overview of the Opportunity The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a new Request for Information (RFI) titled “Biosafety Level 4 Preclinical and Nonclinical Support for Medical Countermeasure Development (BSL4)”. Issued July 9, 2026, the RFI is a market research exercise to map out who can deliver preclinical and nonclinical

BARDA RRPV RFI Seeks Partners for BSL4 Studies and Support Services  Read More »

NIAID Renews IMPAc‑TB to Accelerate Tuberculosis Vaccine Development 

Leave a Comment / All Posts, Life Sciences, NIAID / By

Overview of the Opportunity The National Institute of Allergy and Infectious Diseases (NIAID), through the National Institutes of Health (NIH), has issued RFP No. BAA-75N93026R00008 for the Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc‑TB), a five‑year contract program that renews the effort to accelerate TB vaccine development. The goal is to define tissue‑specific and

NIAID Renews IMPAc‑TB to Accelerate Tuberculosis Vaccine Development  Read More »

BARDA’s RFI Explores Repurposing Autoinjector Equipment for New Drug Delivery Devices 

Leave a Comment / All Posts, BARDA, Life Sciences / By

Download the Solicitation Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA) is looking at a specific problem: how to repurpose specialized equipment originally designed to manufacture an emergency autoinjector platform into a broader drug delivery solution. Through the Rapid Response Partnership Vehicle (RRPV), BARDA released a new Request for Information (RFI), “Repurposing Equipment

BARDA’s RFI Explores Repurposing Autoinjector Equipment for New Drug Delivery Devices  Read More »

BARDA Issues RFI on Adjuvanted Egg-Based Influenza Vaccine for Pandemic Preparedness 

Leave a Comment / All Posts, BARDA, Life Sciences / By

Download the Solicitation Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a Request for Information (RFI) titled “Advanced Clinical Development and Licensure of an Adjuvanted Egg-based Influenza Vaccine.” Through this market research effort, BARDA is seeking feedback from industry, academia, and other stakeholders to

BARDA Issues RFI on Adjuvanted Egg-Based Influenza Vaccine for Pandemic Preparedness  Read More »

Scroll to Top